Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 19/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919581 | 0.89 | CYP3A4 (0.39) | CYP3A4CCR5CXCR4 | |
| SCHEMBL3922314 | 0.88 | CYP3A4 (0.33) | CYP3A4CCR5 | |
| Benzamide SCHEMBL3918735 | 0.88 | CYP3A4 (0.40) | CYP3A4CCR5CYP2D6CYP2C9CXCR4 | |
| SCHEMBL3916142 | 0.88 | CYP3A4 (0.35) | CYP3A4CCR5CYP2D6CYP2C9 | |
| SCHEMBL1800972 | 0.84 | L3MBTL1 (0.42) | CYP3A4 | |
| SCHEMBL3916109 | 0.83 | CYP3A4 (0.32) | CYP3A4CCR5 | |
| SCHEMBL4036932 | 0.82 | CYP3A4 (0.40) | CYP3A4CCR5CYP2D6CYP2C9CXCR4 | |
| SCHEMBL4035065 | 0.82 | CYP3A4 (0.38) | CYP3A4CCR5CXCR4 | |
| SCHEMBL3922889 | 0.81 | MEN1 (0.31) | — | |
| SCHEMBL1800047 | 0.81 | CCR5 (0.38) | CYP3A4CCR5CYP2D6CYP2C9CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | claimed |
| EP-1730144-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-06-10 | — | — | EP | claimed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | THPO, UGT1A8, UGT1A4 | CYP3A4 12/4885CCR5 2852/4885CYP2D6 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.